NCT07591077CompletedPhase 2/3
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents With Type 1 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- First submitted
- 9 May 2026
- Start date
- 20 Nov 2024
- Primary completion date
- 20 Nov 2025
- Lead sponsor
- Ain Shams University
- NCT number
- NCT07591077
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 86
- From 20 Nov 2024 to the primary completion date, 20 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with other types of diabetes e.g. T2DM, maturity onset diabetes of the young (MODY).
- Presence of contraindication for empagliflozin e.g. History of serious hypersensitivity reaction to empagliflozin, end-stage renal disease, or dialysis.
Other
- Other types of nephropathy.
Who the study is looking for
- Patients with T1DM according to the international society of pediatric and adolescent diabetes (ISPAD). (Couper et al., ISPAD 2022).
- Age 10- 18 years old.
- Diabetic nephropathy according to ISPAD. (Couper et al., ISPAD 2022).
- eGFR \> 30 ml/min per 1.73 m2
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.